The guidelines include a Class 1 recommendation, “In patients with symptomatic chronic HFrEF, SGLT2 inhibitors are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes”. Here, SLC5A2 is linked to hydrops fetalis.